198 related articles for article (PubMed ID: 22768537)
1. [Prospective pioglitazone clinical trial in macrovascular events].
Asanuma H; Kitakaze M
Nihon Rinsho; 2012 May; 70 Suppl 3():301-8. PubMed ID: 22768537
[No Abstract] [Full Text] [Related]
2. [Macrovascular secondary prevention with pioglitazone in diabetics. PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events)].
Nitschmann S
Internist (Berl); 2007 Jan; 48(1):89-90; discussion 90-1. PubMed ID: 17187243
[No Abstract] [Full Text] [Related]
3. PROactive: time for a critical appraisal.
Betteridge DJ; DeFronzo RA; Chilton RJ
Eur Heart J; 2008 Apr; 29(8):969-83. PubMed ID: 18375395
[TBL] [Abstract][Full Text] [Related]
4. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
Wilcox R; Kupfer S; Erdmann E;
Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
[TBL] [Abstract][Full Text] [Related]
5. [Too positive comment on glitazones].
Lindberg M
Ugeskr Laeger; 2007 Feb; 169(8):733; author reply 733. PubMed ID: 17338040
[No Abstract] [Full Text] [Related]
6. [Pioglitazone in evaluation by IQWiG (Institute for Quality and Cost Effectiveness in Public Health)--tunnel vision instead of broad view].
MMW Fortschr Med; 2008 Aug; 150(32-35):56-7. PubMed ID: 19009700
[No Abstract] [Full Text] [Related]
7. How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?
Freemantle N
BMJ; 2005 Oct; 331(7520):836-8. PubMed ID: 16210286
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk and cardiometabolic protection: role of glitazones.
Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
[TBL] [Abstract][Full Text] [Related]
9. Organ protection in the secondary prevention of type 2 diabetes.
Schernthaner G
Drugs Today (Barc); 2006 Dec; 42 Suppl C():17-23. PubMed ID: 17245477
[TBL] [Abstract][Full Text] [Related]
10. The PROactive trial (PROspective pioglitAzone Clinical Trial In macroVascular Events): what does it mean for primary care physicians?
Singaram V; Pratley R
Diab Vasc Dis Res; 2007 Sep; 4(3):237-40. PubMed ID: 17907116
[TBL] [Abstract][Full Text] [Related]
11. [How does the PROactive Study change therapy of diabetes?].
Erdmann E
MMW Fortschr Med; 2005 Oct; 147(41):6. PubMed ID: 16270501
[No Abstract] [Full Text] [Related]
12. Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).
Erdmann E; Spanheimer R; Charbonnel B;
J Diabetes; 2010 Sep; 2(3):212-20. PubMed ID: 20923486
[TBL] [Abstract][Full Text] [Related]
13. [World news in age-related diabetes: blood sugar lowering can improve prognosis].
Einecke D
MMW Fortschr Med; 2005 Sep; 147(38):1. PubMed ID: 16218218
[No Abstract] [Full Text] [Related]
14. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone.
Betteridge DJ
Fundam Clin Pharmacol; 2009 Dec; 23(6):675-9. PubMed ID: 19744248
[TBL] [Abstract][Full Text] [Related]
15. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
16. [The effect of glitazones on the progression of type 2 diabetes and on cardiovascular endpoints].
Schatz H
Dtsch Med Wochenschr; 2005 Aug; 130(31-32):1825-30. PubMed ID: 16052448
[No Abstract] [Full Text] [Related]
17. [Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
Veneman TF
Ned Tijdschr Geneeskd; 2006 Apr; 150(16):931-2; author reply 932-3. PubMed ID: 16686096
[No Abstract] [Full Text] [Related]
18. [Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
Heine RJ
Ned Tijdschr Geneeskd; 2006 Apr; 150(16):930-1; author reply 932-3. PubMed ID: 16686095
[No Abstract] [Full Text] [Related]
19. [Evidences demonstrating the effects of prevention of major adverse cardiovascular events and anti-atherosclerotic actions of pioglitazone--special emphasis on PROactive study and PERISCOPE study].
Kawamori R
Nihon Rinsho; 2011 Jan; 69 Suppl 1():671-7. PubMed ID: 21766679
[No Abstract] [Full Text] [Related]
20. [Glitazones critically evaluated].
Schernthaner G
Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
[No Abstract] [Full Text] [Related]
[Next] [New Search]